TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
USC scientists report a laboratory method for expanding granulocyte-monocyte progenitors (GMPs), immature immune cells that can be engineered to recognize cancer markers. In mouse experiments, the cells established themselves in bone marrow, generated new immune cells and slowed blood cancers and solid tumors; human safety and benefit have not been established.
Researchers at the University of Southern California report that they have developed a way to grow and genetically modify granulocyte-monocyte progenitors (GMPs), immature immune cells that can produce cancer-fighting cells. In experiments in mice, the engineered cells settled in bone marrow, generated new immune cells and slowed the progression of blood cancers and solid tumors, according to the study published in Cell. The work offers a possible route around cell-therapy manufacturing limits, but it does not establish that the approach is safe or effective in people.
The USC Stem Cell-led team focused on GMPs, which normally develop into macrophages and other immune cells. The researchers report that a defined mixture of chemicals allowed GMPs to multiply extensively in the laboratory without prematurely maturing. The expanded cells retained their identity and ability to produce functioning immune cells, the study says.
The researchers also genetically modified the progenitors so that the immune cells they produced could recognize specific cancer markers and strengthen broader immune responses. In mouse experiments, the engineered cells established themselves in bone marrow and continued producing immune cells. The team reported slower progression of both blood cancers and solid tumors in the animals; the supplied report does not give effect sizes or detailed comparisons.
Corresponding author Qi-Long Ying, a professor of stem cell biology and regenerative medicine at USC’s Keck School of Medicine, said the study establishes a scalable and engineerable GMP platform. The report identifies Shi Yue, MD, of Ying’s laboratory, as the study’s first author. The results are preclinical: the source describes experiments in mice, not a clinical trial in patients.
A New Route to Cell Therapy Supply
Many engineered cell therapies depend on producing enough immune cells for treatment, while maintaining their function through manufacturing and delivery. The USC approach aims to address that supply problem by expanding an earlier-stage cell that can generate mature immune defenders when needed, rather than trying to grow large quantities of mature macrophages directly.
The strategy may be relevant to solid tumors, where engineered T-cell treatments have faced challenges and macrophages’ ability to move into tissues is of interest. But the mouse findings do not show that GMP-derived cells will reach human tumors, persist safely, or improve patient outcomes. The work is a potential platform for further research, not a ready-to-use cancer treatment.
As an affiliate, we earn on qualifying purchases.
Why Researchers Started With GMPs
Macrophages can engulf unwanted material and send signals that influence other immune cells. Their capacity to enter tissues has made them candidates for cancer research. However, according to the source report, mature macrophages are difficult to expand and genetically modify in large quantities, can be damaged by freezing and storage, and may accumulate in organs such as the lungs and liver after administration. Their limited persistence can also restrict how long a treatment acts.
The USC team addressed those manufacturing obstacles by working with GMP progenitors rather than mature macrophages. The finding also bears on blood-cell biology: progenitor cells are generally viewed as more developmentally limited than hematopoietic stem cells, which can produce many blood and immune-cell types. The researchers report that GMPs retained self-renewal under their laboratory conditions while keeping the ability to produce functional immune cells. That result is specific to the experimental system and does not mean all progenitor cells behave this way.
“The study establishes a scalable and engineerable GMP platform for cellular immunotherapy and introduces concepts that we believe could have broad implications for both cancer immunotherapy and stem cell biology.”
— Qi-Long Ying, corresponding author and USC professor
As an affiliate, we earn on qualifying purchases.
Human Testing Remains Unreported
The source material describes mouse experiments and laboratory cell expansion, but does not report human trials, patient outcomes, or regulatory review. It is not clear how well the engineered cells would function in people, what dose might be needed, or how long any effect would last. The report also does not provide detailed figures for tumor slowing, survival, side effects, or comparisons with existing treatments.
Safety questions remain, including how engineered cells would behave over time, whether they could affect healthy tissues, and whether they would trigger harmful immune reactions. The study’s findings should not be read as evidence that a cancer treatment is available or that the method will work across cancer types.
As an affiliate, we earn on qualifying purchases.
Further Studies Must Test Safety
The reported next step is further research to establish whether the platform can be developed into a treatment. Before any clinical use, researchers would need to test the cells’ behavior, persistence, tumor targeting and safety in additional studies, then determine whether clinical trials are justified. The supplied report does not announce a trial timeline or a planned start date.
Readers should watch for follow-up studies that provide detailed animal results, clarify how the engineered cells are made and controlled, and report whether human testing is proposed. Until such evidence is available, the finding remains a preclinical research result.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the USC researchers develop?
They report a method to expand GMP progenitor cells in the laboratory while preserving their ability to produce immune cells, and to genetically modify them to recognize cancer markers.
Did the approach work in people?
The supplied report describes experiments in mice, not human trials. It does not establish safety or effectiveness for patients.
What cancers were tested?
The report says the engineered cells slowed progression of blood cancers and solid tumors in mice. It does not specify detailed results for particular cancer types in the provided material.
Why use progenitor cells instead of mature macrophages?
The researchers aimed to expand an earlier-stage cell that can generate macrophages. Mature macrophages can be difficult to multiply and modify in large quantities, according to the report.
When could this become a treatment?
No clinical-trial schedule or treatment timeline is given. Additional research would be needed to assess safety and determine whether testing in people is appropriate.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
